Pharmaceutical Companies Raise Drug Prices 289 Percent on Key Medications

President Trump has identified lowering prescription drug prices as a clear priority, repeatedly asserting that Americans should not be forced to pay more for medicine than patients in other developed countries. However, pharmaceutical companies have publicly welcomed this message while their actions indicate a more complex reality.

According to recent data, over 350 drugs will experience list price increases for 2026. Many adjustments are modest, but others are significant: Demerol, a painkiller used in obstetrics, will see a 289 percent increase; fragmin, an anti-blood clot treatment, will rise by 149 percent; erythrocin, a branded antibiotic, will cost 80 percent more in 2026; cyclokapron, a hemophilia drug, is priced 49 percent higher; and epinephrine and marcaine, both critical medications for life-threatening conditions, will increase by 22 percent each.

oxycontin, the opioid at the root of the crisis still marketed by Purdue Pharma, will also receive a 9 percent price hike—a demonstration that a drug responsible for significant harm in regions like Appalachia continues to generate substantial profits for its manufacturer.

Pharmaceutical companies are simultaneously targeting the 340B drug discount program, which provides discounted medications to safety-net hospitals and clinics without cost to taxpayers. These savings support low-income and uninsured patients in rural states including Missouri, Arkansas, Louisiana, Kentucky, West Virginia, and Tennessee.

The industry’s efforts to dismantle this program while raising prices above inflation rates present a contradictory approach that could undermine the cost-saving mechanisms they advocate.

Additionally, drugmakers are supporting proposals to restrict pharmacy benefit managers (PBMs), which negotiate discounts for patients. Such proposals would prevent PBMs from earning additional profits when securing better savings for insurers and employers—effectively discouraging cost reduction efforts. This could lead to PBMs closing down entirely, leaving patients with no alternative but to pay the high list prices set by pharmaceutical companies.

The industry’s actions do not constitute a public rejection of Trump’s drug pricing agenda. However, the combination of price hikes and efforts to dismantle cost-control mechanisms contradicts the stated goal of reducing costs. This situation also impacts Republican efforts to maintain House control, which Trump has identified as essential for avoiding a third impeachment by Democrats.

If the objective is genuinely to lower drug prices, it remains unclear why pharmaceutical companies continue to target systems that facilitate such reductions.